JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release and Investor Deck for the quarter and year ended March 31, 202420-05-2024
20-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On May 20, 2024 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2024
Please find enclosed Audited Financial Result for the year ended March 31, 2024 along with Indepedent Auditors Report20-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 20, 2024 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2024
Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2024. In this regard, kindly find enclosed the following: 1.Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024. 2. The Board recommended a dividend of Rs. 5/- (100%) per equity share for the financial year ended March 31, 2024.20-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Acquisition
We wish to inform you that Jagsonpal Pharmaceuticals Limited (''the Company'') has signed the Business Transfer Agreement ("BTA") for the purchase of India and Bhutan business of Yash Pharma along with the brands and associated trademarks.16-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Considering The Audited Financial Result Of The Company For The Quarter And Year Ended March 31, 2024 And Recommendation Of Dividend, If Any, For The Financial Year Ended March 31, 2024.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 ,inter alia, to consider and approve the Audited Financial Result of the company for the quarter and year ended March 31, 2024 and recommendation of dividend, if any, for the financial year ended March 31, 2024.13-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In term of Regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the press release issued by the company titled " JAGSONPAL LAUNCHES WOMEN''S HEALTH WEBSITE - WWW.MYSAKHI.IN"10-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for issuance of Letter of Confirmation under SEBI LODR Regulations, 201507-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Pursuant to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended, we are pleased to inform you that the Nomination and Remuneration Committee has issued and alloted 3000 Equity Shares of Rs. 5 Each under JPL ESOP 2022T to eligible employee of the Company.04-05-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company JAGSONPAL PHARMACEUTICALS LTD. 2 CIN NO. L74899DL1978PLC009181 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-24 , 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2022-23, 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Abhishek JoshiDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Ashish Lakhotia Designation : -Chief Financial Officer Date: 29/04/202429-04-2024
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyJAGSONPAL PHARMACEUTICALS LTD. 2CIN NO.L74899DL1978PLC009181 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Abhishek Joshi Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Ashish Lakhotia Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2024